Interview: Roche to seize leap-frog opportunity in lung cancer - (Business Insider via NewsPoints Desk)

  • Roche CEO Severin Schwan said the drugmaker could grab a leading position in the treatment of previously untreated lung cancer, as reported Business Insider Wednesday.

  • "We have a real chance to be at the forefront here," commented Schwan, continuing "our ambition is to become a clear leader in the field of cancer immunotherapies."

  • The CEO's remarks come after the immunotherapy Tecentriq in combination with Avastin drastically reduced the risk of lung cancer progression.

  • "We have the potential to get into the lead in first-line lung cancer," Schwan remarked, adding "in all likelihood we have a medicine here that will potentially change the standard of care…but we will also have to see how it compares with other therapies."

  • Roche indicated that while it does not have overall survival data for the combination regimen, initial results are "encouraging," adding that full results are expected in the first half of next year.

  • "On the pipeline side, we're even more de-risked than a year ago…but there is no doubt that the impact from biosimilars will be significant," Schwan cautioned, continuing "on balance, I'm now very confident that we should be able to compensate for this erosion."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.